Compare Bristol-Myers Squibb Co (BMY) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Macy's Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B), while Macy's Inc trades at $23.15 (market cap $5.99B). The key difference: Bristol-Myers Squibb Co is far larger — about 20.2× Macy's Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| BMY | M | |
|---|---|---|
Market Cap | $121.18B | $5.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $25.96 |
52-Week Low | $42.60 | $11.90 |
Enterprise Value | $157.12B | $9.81B |
Dividend Yield | 4.25% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Macy's (M) trades at $22.78, up 0.62% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 9.41 and P/S of 0.28, alongside improving cash flow and a recent earnings beat streak. The 'Bold New Chapter' strategy is driving operational improvements, with Berkshire Hathaway's new stake in Q1 2026 signaling institutional confidence.
The outlook is cautiously optimistic, supported by low valuation and strategic initiatives, but risks include margin pressure from retail sector headwinds and execution challenges in the turnaround plan. Analyst consensus is mixed, with a $24.83 price target suggesting modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
